Biopharmaceutical company Mabwell has announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821).
Boehringer Ingelheim has licensed Synaffix B.V.’s ADC technology, significantly bolstering its ADC portfolio with the goal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback